Mbx Biosciences Inc (MBX) Stock Price, Quote & News

Company Profile

MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism. The company is also developing Imapextide (MBX 1416), a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that i...

Industry: Biotechnology

Sector: Healthcare

Phone: 317 659 0200

Website: mbxbio.com

Address:

11711 North Meridian Street, Suite 300, Carmel, United States

Makingmillions192 May. 13 at 1:06 PM

$LEXX UBS took a large position here in Q4 2025 - https://www.cnbc.com/2026/05/12/this-new-glp-1-play-is-on-a-tear-ubs-sees-nearly-a-50percent-gain-from-here-.html They are looking at biotech GLP-1 plays very closely. $MBX Which has demonstrated ok efficacy and tolerability with a monthly needle injection is trading at a 1.8bn valuation with a 100m cash burn. Lexaria’s technology is probably the largest hidden gem in this entire space. The team needs to do more to share that story as institutions and index funds don’t touch mkt caps this low… $UBS $LLY

0 · Reply

MarketBeat May. 11 at 7:11 PM

https://marketbeat.com/a/8648822/ $MBX MBX Biosciences Obesity Day Spotlights Monthly GLP-1 Hope and Pipeline Push

0 · Reply

fossilmark May. 11 at 3:34 PM

$MBX Impressive obesity update today. $MBX value today is largely based on Canvuparatide. If Metsera was worth up to $10B, $MBX has a lot of room to be re-rated as an obesity platform company.

1 · Reply

notreload_ai May. 11 at 2:15 PM

$MBX drug showed early weight loss up to 7% in 8 weeks, was well tolerated, and may become once-monthly treatment. https://notreload.xyz/xy/mbx-4291-7-weight-loss-in-8-weeks-once-monthly-potential/

0 · Reply

laaarsas May. 8 at 6:34 PM

$MBX Why stock up 15% today?

2 · Reply

laaarsas May. 5 at 5:33 PM

$MBX How important is the upcoming Q2 data? How much could it move the share price?

2 · Reply

laaarsas Apr. 20 at 4:43 PM

$MBX How important is the coming OLE data? How much could it move the share price?

0 · Reply

LewisDaKat Apr. 3 at 12:31 PM

$MBX MBX Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) https://marketwirenews.com/stock/mbx/news/mbx-biosciences-reports-inducement-grant-under-nasda-8891755499107440.html?utm_source=stocktwits

0 · Reply

samjoyst Apr. 2 at 2:31 PM

$MBX anyone noticing a strange pattern today?

0 · Reply

OfficialStocktwitsUser Mar. 26 at 1:41 PM

$MBX RSI: 38.64, MACD: -1.7043 Vol: 1.59, MA20: 29.47, MA50: 34.65 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

MBX Biosciences price target raised to $56 from $50 at Stifel

2026-05-12T10:07:50.000Z - 1 day ago

MBX Biosciences price target raised to $70 from $66 at Barclays

2026-05-12T09:47:56.000Z - 1 day ago

MBX Biosciences price target raised to $86 from $76 at Citizens

2026-05-11T19:43:52.000Z - 1 day ago

MBX Biosciences price target raised to $70 from $50 at Truist

May 11, 2026, 10:30 AM EDT - 1 day ago

MBX Biosciences Transcript: Status update

2026-05-11T13:40:04.000Z - 2 days ago

MBX Biosciences Phase 1 data supports once-monthly dosing for MBX 4291

May 11, 2026, 7:00 AM EDT - 2 days ago

MBX Biosciences Provides Obesity Portfolio Update Including Initial Phase 1 Data for MBX 4291 Supporting Potential for Once-Monthly Dosing

2026-05-07T19:50:45.000Z - 5 days ago

MBX Biosciences reports Q1 EPS (51c), consensus (58c)

2026-05-07T18:59:32.000Z - 5 days ago

MBX Biosciences appoints Mark Soued as chief commercial officer.

ALNY

May 7, 2026, 8:00 AM EDT - 6 days ago

MBX Biosciences Reports First Quarter 2026 Financial Results and Corporate Highlights

May 7, 2026, 7:00 AM EDT - 6 days ago

MBX Biosciences Announces Appointment of Mark Soued as Chief Commercial Officer and Inducement Grant Award

Apr 23, 2026, 8:00 AM EDT - 20 days ago

MBX Biosciences to Host In-Person and Virtual Obesity Day on May 11, 2026 to Discuss Expanding Obesity Portfolio

Apr 3, 2026, 8:00 AM EDT - 5 weeks ago

MBX Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

2026-03-31T11:46:22.000Z - 6 weeks ago

MBX Biosciences initiated with an Outperform at LifeSci Capital

2026-03-23T12:06:18.000Z - 7 weeks ago

Options Volatility and Implied Earnings Moves Today, March 23, 2026

BLRX LAR

2026-03-12T20:10:19.000Z - 2 months ago

MBX Biosciences files automatic mixed securities shelf

2026-03-12T12:06:11.000Z - 2 months ago

MBX Biosciences reports Q4 EPS (49c), consensus (63c)

Mar 12, 2026, 8:00 AM EDT - 2 months ago

MBX Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Highlights

Mar 11, 2026, 3:00 PM EDT - 2 months ago

MBX Biosciences Transcript: Barclays 28th Annual Global Healthcare Conference

Mar 10, 2026, 9:00 AM EDT - 2 months ago

MBX Biosciences Transcript: The Citizens Life Sciences Conference 2026

2026-03-10T12:22:36.000Z - 2 months ago

MBX Biosciences appoints Basbaum as Chief Business Officer

Mar 10, 2026, 8:00 AM EDT - 2 months ago

MBX Biosciences Appoints Karen Basbaum as Chief Business Officer

Mar 9, 2026, 10:21 AM EDT - 2 months ago

CORRECTING & REPLACING -- MBX Biosciences Announces Successful End-of-Phase 2 FDA Meeting and Provides Phase 3 Development Plan for Once-Weekly Canvuparatide for Hypoparathyroidism

2026-03-09T12:13:30.000Z - 2 months ago

MBX Biosciences ‘on track’ to initiate Phase 3 in Q3 following EOP 2 meeting

Mar 9, 2026, 8:00 AM EDT - 2 months ago

MBX Biosciences Announces Successful End-of-Phase 2 FDA Meeting and Provides Phase 3 Development Plan for Once-Weekly Canvuparatide for Hypoparathyroidism

Mar 2, 2026, 9:10 AM EST - 2 months ago

MBX Biosciences Transcript: TD Cowen 46th Annual Health Care Conference

Feb 25, 2026, 11:20 AM EST - 2 months ago

MBX Biosciences Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 23, 2026, 8:00 AM EST - 2 months ago

MBX Biosciences to Participate in Upcoming March Investor Conferences

Feb 11, 2026, 8:00 AM EST - 3 months ago

MBX Biosciences to Participate in Upcoming Investor Conferences

2026-01-27T21:31:18.000Z - 3 months ago

MBX Biosciences initiated with an Overweight at Barclays

2026-01-22T13:17:17.000Z - 3 months ago

MBX Biosciences appoints Laurie Stelzer to board of directors

Jan 22, 2026, 8:00 AM EST - 3 months ago

MBX Biosciences Appoints Laurie Stelzer to Board of Directors as Audit Committee Chair

2026-01-16T13:45:33.000Z - 4 months ago

MBX Biosciences price target raised to $88 from $77 at Guggenheim

Jan 13, 2026, 6:45 PM EST - 4 months ago

MBX Biosciences Transcript: 44th Annual J.P. Morgan Healthcare Conference

2026-01-11T22:20:41.000Z - 4 months ago

MBX Biosciences provides update on clinical programs

2026-01-11T22:15:06.000Z - 4 months ago

MBX Biosciences expects cash to fund operations into 2029

Jan 11, 2026, 4:00 PM EST - 4 months ago

MBX Biosciences to Provide 2026 Outlook and Business Update at 44th Annual J.P. Morgan Healthcare Conference

2026-01-07T13:20:13.000Z - 4 months ago

MBX Biosciences initiated with a Buy at UBS

2026-01-06T19:45:24.000Z - 4 months ago

MBX Biosciences management to meet with Truist

Dec 15, 2025, 8:00 AM EST - 5 months ago

MBX Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13

Dec 2, 2025, 4:00 PM EST - 5 months ago

MBX Biosciences Transcript: Piper Sandler 37th Annual Healthcare Conference

Nov 24, 2025, 10:00 AM EST - 6 months ago

MBX Biosciences Transcript: TD Cowen Treatment Advancements in Obesity and Related Disorders Summit

Nov 19, 2025, 11:00 AM EST - 6 months ago

MBX Biosciences Transcript: Jefferies London Healthcare Conference 2025

Nov 18, 2025, 8:00 AM EST - 6 months ago

MBX Biosciences to Participate in the 37th Annual Piper Sandler Healthcare Conference

Nov 12, 2025, 3:20 PM EST - 6 months ago

MBX Biosciences Transcript: Stifel 2025 Healthcare Conference

Nov 10, 2025, 3:30 PM EST - 6 months ago

MBX Biosciences Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 6, 2025, 8:00 AM EST - 6 months ago

MBX Biosciences Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights

Nov 3, 2025, 9:58 AM EST - 6 months ago

Biotech is back. Here's why these rallying stocks belong in your portfolio now.

ABBV ALNY AMGN BMY LLY MDGL MEDI

Oct 20, 2025, 8:00 AM EDT - 7 months ago

MBX Biosciences to Participate in November Investor Conferences

Sep 30, 2025, 10:00 AM EDT - 8 months ago

MBX Biosciences Transcript: Stifel Virtual Cardiometabolic Forum

Sep 29, 2025, 8:00 AM EDT - 8 months ago

MBX Biosciences to Participate in the Stifel 2025 Virtual Cardiometabolic Forum

Sep 24, 2025, 9:15 PM EDT - 8 months ago

MBX Biosciences Announces Pricing of Upsized Public Offering

Sep 22, 2025, 4:14 PM EDT - 8 months ago

MBX Biosciences Announces Proposed Public Offering

Sep 22, 2025, 8:00 AM EDT - 8 months ago

MBX Biosciences Transcript: Study Update

Sep 22, 2025, 7:00 AM EDT - 8 months ago

MBX Biosciences Announces Once-Weekly Canvuparatide Achieved Primary Endpoint in Phase 2 Trial with 63% Responder Rate at 12 Weeks; 79% Responder Rate at 6 Months in Open-Label Extension

Sep 19, 2025, 4:18 PM EDT - 8 months ago

MBX Biosciences to Provide Topline Results from its Phase 2 Trial of Potential Once-Weekly Canvuparatide for Hypoparathyroidism (HP) on Monday, September 22

Sep 4, 2025, 8:00 AM EDT - 8 months ago

MBX Biosciences Doses First Participant in Phase 1 Trial of MBX 4291 for the Treatment of Obesity

Aug 7, 2025, 8:00 AM EDT - 9 months ago

MBX Biosciences Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights

Jun 23, 2025, 8:00 AM EDT - 11 months ago

MBX Biosciences Appoints Andreas Moraitis, M.D., as Senior Vice President of Clinical Development

Jun 16, 2025, 8:00 AM EDT - 11 months ago

MBX Biosciences Announces IND Submission of MBX 4291, its Long-acting GLP1/GIP Receptor Co-agonist Prodrug for the Treatment of Obesity

Jun 10, 2025, 8:00 AM EDT - 1 year ago

MBX Biosciences to Present at the American Diabetes Association 85th Scientific Sessions

Jun 9, 2025, 10:40 AM EDT - 1 year ago

MBX Biosciences Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

Jun 4, 2025, 2:00 PM EDT - 1 year ago

MBX Biosciences Transcript: Jefferies Global Healthcare Conference 2025

May 21, 2025, 3:35 PM EDT - 1 year ago

MBX Biosciences Transcript: RBC Capital Markets Global Healthcare Conference 2025

May 20, 2025, 8:00 AM EDT - 1 year ago

MBX Biosciences to Participate in June Investor Conferences

May 12, 2025, 8:00 AM EDT - 1 year ago

MBX Biosciences Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

May 7, 2025, 3:00 PM EDT - 1 year ago

MBX Biosciences Transcript: The Citizens JMP Life Sciences Conference 2025

Apr 22, 2025, 8:00 AM EDT - 1 year ago

MBX Biosciences to Participate in Citizens and RBC May Investor Conferences

Apr 7, 2025, 8:00 AM EDT - 1 year ago

MBX Biosciences Transcript: 24th Annual Needham Virtual Healthcare Conference

Mar 26, 2025, 8:00 AM EDT - 1 year ago

MBX Biosciences to Participate in the 24th Annual Needham Virtual Healthcare Conference

Mar 17, 2025, 8:00 AM EDT - 1 year ago

MBX Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights

Mar 5, 2025, 8:00 AM EST - 1 year ago

MBX Biosciences Announces Additions to Leadership Team

Mar 3, 2025, 10:30 AM EST - 1 year ago

MBX Biosciences Transcript: TD Cowen 45th Annual Healthcare Conference

Mar 3, 2025, 8:00 AM EST - 1 year ago

MBX Biosciences Completes Enrollment in Phase 2 Avail™ Trial of MBX 2109 (Canvuparatide) for Hypoparathyroidism

Feb 18, 2025, 8:00 AM EST - 1 year ago

MBX Biosciences to Participate in March Investor Conferences

Feb 11, 2025, 8:40 AM EST - 1 year ago

MBX Biosciences Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference 2025

Feb 5, 2025, 2:00 PM EST - 1 year ago

MBX Biosciences Transcript: Guggenheim SMID Cap Biotech Conference

Jan 14, 2025, 5:15 PM EST - 1 year ago

MBX Biosciences Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 7, 2025, 8:30 AM EST - 1 year ago

MBX Biosciences Transcript: Study Result

Jan 7, 2025, 7:00 AM EST - 1 year ago

MBX Biosciences Announces Positive Phase 1 Topline Results for MBX 1416 for the Treatment of Post-bariatric Hypoglycemia

Nov 20, 2024, 10:30 AM EST - 1 year ago

MBX Biosciences Transcript: Jefferies London Healthcare Conference 2024

Nov 18, 2024, 3:00 PM EST - 1 year ago

MBX Biosciences Transcript: Stifel 2024 Healthcare Conference

Nov 18, 2024, 8:00 AM EST - 1 year ago

MBX Biosciences Announces Last Subject Last Visit in Phase 1 Trial of MBX 1416 for the Treatment of Post-Bariatric Hypoglycemia

Nov 12, 2024, 3:30 PM EST - 1 year ago

MBX Biosciences Transcript: Guggenheim Inaugural Global Healthcare Innovation Conference

Oct 28, 2024, 8:00 AM EDT - 1 year ago

MBX Biosciences to Participate in Upcoming November Investor Conferences

Sep 30, 2024, 8:00 AM EDT - 1 year ago

MBX Biosciences Presents MBX 2109 Phase 2 Avail™ Hypoparathyroidism Trial Rationale and Design at the ASBMR 2024 Annual Meeting

Sep 16, 2024, 4:05 PM EDT - 1 year ago

MBX Biosciences Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Sep 13, 2024, 12:36 PM EDT - 1 year ago

MBX Biosciences shares surge 44% in blockbuster Nasdaq debut

Sep 12, 2024, 7:20 PM EDT - 1 year ago

MBX Biosciences raises $163.2 mln in US IPO

Sep 12, 2024, 7:11 PM EDT - 1 year ago

MBX Biosciences Announces Pricing of Initial Public Offering

Makingmillions192 May. 13 at 1:06 PM

0 · Reply

MarketBeat May. 11 at 7:11 PM

https://marketbeat.com/a/8648822/ $MBX MBX Biosciences Obesity Day Spotlights Monthly GLP-1 Hope and Pipeline Push

0 · Reply

fossilmark May. 11 at 3:34 PM

$MBX Impressive obesity update today. $MBX value today is largely based on Canvuparatide. If Metsera was worth up to $10B, $MBX has a lot of room to be re-rated as an obesity platform company.

1 · Reply

notreload_ai May. 11 at 2:15 PM

$MBX drug showed early weight loss up to 7% in 8 weeks, was well tolerated, and may become once-monthly treatment. https://notreload.xyz/xy/mbx-4291-7-weight-loss-in-8-weeks-once-monthly-potential/

0 · Reply

laaarsas May. 8 at 6:34 PM

$MBX Why stock up 15% today?

2 · Reply

laaarsas May. 5 at 5:33 PM

$MBX How important is the upcoming Q2 data? How much could it move the share price?

2 · Reply

laaarsas Apr. 20 at 4:43 PM

$MBX How important is the coming OLE data? How much could it move the share price?

0 · Reply

LewisDaKat Apr. 3 at 12:31 PM

0 · Reply

samjoyst Apr. 2 at 2:31 PM

$MBX anyone noticing a strange pattern today?

0 · Reply

OfficialStocktwitsUser Mar. 26 at 1:41 PM

0 · Reply

Just_me_idea Mar. 24 at 8:56 PM

$MBX Promising biotech with a peptide platform applicable across multiple indications, including obesity, strong Phase 2 results, and an upcoming very short Phase 3 — assuming it isn’t acquired before then. Cash secured. And to top it off, Karen Basbaum, the serial deal‑maker, just joined as CBO — guess why…

0 · Reply

CEOBuysDisclosures Mar. 16 at 2:05 PM

$MBX CEO purchased 18,500 shares at $28.41 for a total of $525,663. Hawryluk P. Kent now owns 1,215,051 shares. https://ceo-buys.com

0 · Reply

Tomakak Mar. 13 at 2:38 PM

$MBX another dilution ahead, why? They have cash till 2029

0 · Reply

Benalish Mar. 10 at 5:57 PM

$MBX

0 · Reply

Quantumup Mar. 2 at 12:23 PM

H.C. Wainwright⬆️ $GPCR's PT to $114 from $90 and reiterated at a Buy rating. $VKTX $LLY $NVO $MBX AZN AMGN RHHBY PFE Here's what H.C. Wainwright said in its note: https://x.com/Quantumup1/status/2028443691505914151?s=20

0 · Reply

BillionerOfKing Feb. 21 at 12:23 PM

$MBX Current Stock Price: $34.80 Contracts to trade: $35.0 MBX Mar 20 2026 Call Entry: $2.50 Exit: $4.39 ROI: 76% Hold ~26 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

PamelaBarbieri520 Feb. 21 at 7:19 AM

$MBX Microcap with limited disclosure and speculative trading. Fundamentals are unclear. Liquidity risk remains high.

0 · Reply

OfficialStocktwitsUser Feb. 17 at 12:38 AM

$MBX RSI: 54.65, MACD: 0.7757 Vol: 2.19, MA20: 38.17, MA50: 34.27 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

russwise Feb. 12 at 7:38 PM

$MBX Short interest dropped again from 2.3 to 1.97 million shares.

0 · Reply

SocioCobb Feb. 11 at 2:13 PM

$MBX You do the math. I find consistent 2x + bangers!

0 · Reply

NeuralNetIQ Feb. 4 at 1:41 PM

$MBX is a medical device company focused on ear, nose, and throat treatments; its products address niche surgical needs, limiting its total addressable market.

0 · Reply

StockConsultant Feb. 2 at 2:30 PM

$MBX MBX Biosciences stock watch, pullback to 36.36 support area with high trade quality at https://stockconsultant.com/?MBX

0 · Reply

Market Cap	1.91B
Revenue (ttm)	0.00
Net Income (ttm)	-86.97M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	1,052,600
Avg Vol	558,686
Day's Range	N/A - N/A
Shares Out	47.60M
Stochastic %K	48%
Beta	0.78
Analysts	Strong Sell
Price Target	$62.55